BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset

Clinical-stage radioligand therapy developer BoomRay Pharmaceuticals announced it has entered into an exclusive arrangement, though the provided article excerpt does not identify the counterparty, asset, financial terms, or scope. The announcement is directionally positive for BoomRay's precision-oncology pipeline, but the truncated disclosure prevents an assessment of the transaction's financial or commercial significance.